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Abstract: A new type of berberine derivatives was obtained by the reaction of berberrubine with
aliphatic sulfonyl chlorides. The new polycyclic compounds have a sultone ring condensed to C and
D rings of a protoberberine core. The reaction conditions were developed to facilitate the formation
of sultones with high yields without by-product formation. Thus, it was shown that the order of
addition of reagents affects the composition of the reaction products: when sulfochlorides are added
to berberrubine, their corresponding 9-O-sulfonates are predominantly formed; when berberrubine is
added to pre-generated sulfenes, sultones are the only products. The reaction was shown to proceed
stereo-selectively and the cycle configuration was confirmed by 2D NMR spectroscopy. The inhibitory
activity of the synthesized sultones and their 12-brominated analogs against the DNA-repair enzyme
tyrosyl-DNA phosphodiesterase 1 (Tdp1), an important target for a potential antitumor therapy, was
studied. All derivatives were active in the micromolar and submicromolar range, in contrast to the
acyclic analogs and 9-O-sulfonates, which were inactive. The significance of the sultone cycle and
bromine substituent in binding with the enzyme was confirmed using molecular modeling. The
active inhibitors are mostly non-toxic to the HeLa cancer cell line, and several ligands show synergy
with topotecan, a topoisomerase 1 poison in clinical use. Thus, novel berberine derivatives can be
considered as candidates for adjuvant therapy against cancer.
Keywords: berberine; berberrubine; cancer; Tdp1 inhibitor; DNA repair enzyme; SAR; molecular
modeling; sultone; sulfonate
1. Introduction
The isoquinoline alkaloid berberine 1 (Figure 1) is one of the most widespread mem-
bers of the protoberberine alkaloids family, and is found in plants of the Rhoeadales,
Ranunculáceae, Berberidaceae, Menispermáceae, Rutaceae and other families [1]. Berber-
ine is primarily known for its hypoglycemic and hypocholesterolemic activity [2–4], and
other indications are also known [5,6].
A common method to obtain improved biological activity involves chemical modifica-
tions of a hit or lead compound.
The addition of various functional groups on the berberine scaffold is widely used
to create highly active agents with antibacterial, fungicidal, hypocholesterolemic, and
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anticancer effects [7–10]. The sulfonate moiety, which is common in, for example, cardio-
vascular and antiviral drugs, was used as pharmacophore to the enhance hypolipidemic
properties of berberine derivatives. The reaction of the demethylated analogue of berberine,
berberrubine 2 (Figure 1), with sulfochlorides was previously used to obtain 9-O-sulfonates
of berberine 3 (Figure 1), described as hypocholesterolemic [11] and anti-inflammatory [12]
agents. We have shown that berberine aryl-9-O-sulfonates 3 inhibit DNA-repair enzyme
tyrosyl-DNA phosphodiesterase 1 (Tdp1).
Figure 1. The molecular structures of isoquinoline alkaloid berberine 1, berberrubine 2 and sulfonate
derivatives of 9-demetoxyberberine 3.
Tdp1 is a eukaryotic enzyme that removes the 3′ ends of DNA after aberrant topoi-
somerase activity, and can process blocked 3′ ends generated by DNA damaging agents
and nucleoside analogs in addition to hydrolyzing 3′-phosphotyrosyl residues (reviewed
in Reference [13]). The hypothesis that Tdp1 is responsible for drug resistance in some
cancers is supported by a number of studies: Tdp1 deficiency in Tdp1 knockout mice and
in human cell lines with a mutation, which reduces the activity of this enzyme, leads to
hypersensitivity to camptothecin or its derivatives [14–16]. Suppression of Tdp1 expression
with minocycline enhances the antimetastatic effect of irinotecan and increases the lifespan
of the experimental animals [17]. Conversely, in cells with increased Tdp1 expression,
Top1 poisons cause less DNA damage [18,19]. Furthermore, Tdp1 overexpression protects
colorectal cancer cells from irinotecan mediated cell death [20]. Thus, Tdp1 is a promising
therapeutic target, and its inhibitors are expected to significantly synergize the effects of
current anti-tumor therapies, including topoisomerase poisons and other DNA damaging
agents. Indeed, it was found that combined treatment of tumor cells with Tdp1 inhibitors
and anticancer drugs camptothecin or topotecan greatly increased the activity of these
pharmaceuticals in in vitro [21–28] and in vivo [29,30] experiments. Nevertheless, to the
best of our knowledge, no Tdp1 inhibitors have reached human clinical trials. A few classes
of Tdp1 inhibitors, including natural products derivatives, are known such as furamidines
4 [31,32], derivatives of bile acids 5 [33], of lichen metabolite usnic acid 6 [34], monoter-
penoid derivatives 7 [22,35] and oxinitidine 8 [36] with inhibitory activity in the micro or
submicromolar ranges (Figure 2).
Berberine is known to enhance cancer cell chemosensitivity to irinotecan, semisyn-
thetic derivative of camptothecin. Additionally, the berberine anticancer effect could be
enhanced via derivatization [37]. Berberine aryl-9-O-sulfonates 3 as Tdp1 inhibitors sensi-
tize HeLa cells to the anticancer drug topotecan [38]. Such a mechanism of action suggests
an enhancement of the effect of established chemotherapeutic drugs, making inhibitors of
Tdp1 a promising new adjunctive anticancer therapy.
According to the results of the above-mentioned work by Gladkova et al. [38], it
should be noted that berberrubine in the reaction with aliphatic sulfochlorides gives the
corresponding 9-O-sulfonates in low to moderate yields, without any information about
other reaction products.
The crystal structure of Tdp1 has been available for molecular modelling studies to
support the development of new inhibitors, e.g., for the binding predictions of newly
synthesized derivatives [39,40], in guiding the synthetic work of new inhibitors [29,35]
and finally in identifying new hit matter using structure-based virtual screening [21,33].
Recently, a crystal structure of Tdp1 was published with a co-crystalized ligand [41]; it
was found by keeping three crystalline water molecules that the binding mode of the co-
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crystalized ligand reproduced verifying the robustness of the model [25]. It can therefore
be stated that a reliable molecular model has emerged that correlates with activity results.
The primary aim of this study was to investigate the reactions of berberrubine with
aliphatic sulfochlorides, identification of their main reaction pathways, and isolation and
characterization of the reaction products. Furthermore, we wished to assess the inhibitory
activity against the Tdp1 of the products.
Figure 2. A few classes of known Tdp1 inhibitors.
2. Results and Discussion
2.1. Chemistry
2.1.1. Reaction of Berberrubine 2 with Alkylsulphochlorides
The formation of sulfonates during the reaction of berberine and its derivatives with
RSO2Cl is well-known [11,38]. We have shown earlier that the interaction of berberrubine
2 with alkyl sulfochlorides 9a–d at standard conditions (methylene chloride as a solvent
and triethylamine as a base) leads to the formation of sulfonates 3a–d in 7–50% yields [38].
The target 3a–d sulfonates were isolated by filtration from the reaction mixture. While in
some cases the yield of the target sulfonates was low, the composition of the mother liquor
has not been studied in any of the works mentioned.
During additional investigations in the current work, we found, for the first time, that
besides the expected sulfonates 3a–d, cyclic sulfonates and sultones 10a–d (Scheme 1), are
formed and remained in the mother-liquor after filtration. To form 10a–d, sulphochlorides
9a–d need to react with the electrophilic and nucleophilic centers of berberine at positions
8 and 9, respectively, to form a new six-membered cycle condensed with C and D rings.
The ratio of products 3 and 10 in the reaction mixtures varied from 1:5, in the case
of methanesulfonyl chloride 9a, to 3:1 in the reaction with butanesulfonyl chloride 9c
according to NMR. In the series of alkylsulfonates 3a–d, we observed a decrease in solubility
in methylene chloride with an increasing length of the alkyl moiety, which resulted in
more sulfonates with longer alkyl substituents precipitating, and therefore, in higher yields
(yield increased from 7% for compound 3a to 50% for compound 3d). In order to isolate
pure sultones 10a–d, the mother liquor remaining after filtration of the precipitate was
washed with water and then the product was purified by column chromatography on silica
gel. New cyclic derivatives of berberine, sultones, were isolated in yields from 3% to 40%.
Molecules 2021, 26, 1945 4 of 23
Scheme 1. Reaction of berberrubine 2 with alkylsulphochlorides 9a–d.
2.1.2. Investigation into the Reaction Mechanism
The observed formation of cyclic and noncyclic sulfonates can be explained by a two-
step reaction mechanism (mechanism A, Scheme 2) with the addition of sulfochloride at the
9-O-position of the berberine backbone to form sulfonate 3 and the subsequent closure of
the cycle at the 8th position to form a new C-C bond leading to the formation of the sulfone
10. To check the possibility of sequential stages processing, the sulfonate 3b was stirred
at room temperature in methylene chloride in the presence of triethylamine. In this case,
a partial conversion of compound 3b to cyclic derivative 10b was observed (Scheme 2).
However, even with prolonged stirring (for 48 h), the conversion did not exceed 50%.
Nevertheless, we have shown that sultone 10b can be formed by a stepwise mechanism. It
is worth noting that incubation of individual sulfone 10b under the reaction conditions did
not lead to the formation of sulfonate 3b, indicating the irreversibility of the second stage.
Scheme 2. The proposed mechanism A of sultone formation.
We also cannot exclude a reaction pathway in which a nucleophilic attack at position
8 occurs initially, followed by closure of the sultone cycle (mechanism B) (Scheme 3).
Scheme 3. Proposed mechanism B of sultone formation.
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An example of a reaction at position 8 is the addition of an acetone molecule to
berberine in alkaline conditions, leading to the formation of compound 11 [42] (Scheme 4),
which, however, does not proceed directly, but through the intermediate formation of
berberinol 12. For berberrubine 2 derivatives, this type of reaction was not described in
the literature.
Scheme 4. Addition of acetone molecule to berberine [42].
To investigate the possibility of primary alkylsulfochloride addition at position 8, we
incubated berberine 1 under reaction conditions with sulfochlorides, including various
bases (triethylamine, NaOH), but no sulfochloride addition products at position 8 (com-
pound 13) were observed according to NMR. In addition, we have shown that incubation
of berberrubine 2 in the presence of NaOH in acetone does not lead to the formation of
the 8-OH derivative 14, the assumed intermediate in the reaction of the addition of alkyl
substituents at position 8 (Scheme 5).
Scheme 5. Attempts to obtain product 13 of the interaction of berberine 2 with alkylsulphocloride 9a
and berberrubinol 14.
The third possible reaction pathway is a synchronous process, a one-step cycloaddition
reaction (mechanism C). This path implies the formation of sulfene 15b from sulfochloride
9b under the action of the base. The sulfene’s dipole attacks both the electrophilic and
nucleophilic centers of the berberrubine backbone (Scheme 6).
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Scheme 6. Possible mechanism C of sultone formation.
Since the synchronous process (mechanism C) involves sulfene 15b, and to determine
the possibility of this reaction pathway, we carried out an experiment in which sulfene
15b was initially generated from sulfochloride 9b by adding an equimolar amount of
triethylamine. When the resulting sulfene 15b was added to berberrubine 2, the reaction
proceeded with a low conversion (~10% in 7 h). Changing the order of the reagent’s
addition, by adding the berberrubine solution to the sulfene solution, led to a significant
increase in the conversion of berberrubine 2, reaching 60% in 4 h. We found that reducing
the concentration of sulphochloride 9b from 0.02 mmol/mL to 0.008 mmol/mL, and
consequently the concentration of sulfene 15b, allows the reaction to proceed with a 100%
conversion in the same 4 h. It may be related to the ability of sulfenes to form dimeric
structures of type 11 in concentrated solutions [43] (Scheme 7).
Scheme 7. Formation of dimers from sulphenes [43].
Decrease of the sulfene 15b solution concentration and slow addition of a previously
prepared mixture of berberrubine 2 and triethylamine in methylene chloride allowed us to
perform the reaction with a complete conversion in 4 h and to only selectively obtain cyclic
sulfonate 10b in high yields without sulfonate 3b impurities. This technique was extended
to the reaction with other sulfochlorides, the target sulfonates 10a–b were isolated in yields
of 64–70% after column chromatography (Scheme 8).
Thus, the analysis of the data obtained in the described series of experiments strongly
indicates the formation of sultones 10a–d by two mechanisms: sequentially, through the
formation of sulfonates 3a–d and the subsequent closing of the sulfone cycle leading to sul-
tones 10a–d, and by the synchronous addition of the sulfene intermediate. By changing the
order of reagent addition, we can influence the reaction pathways and hence the composi-
tion of the reaction mixture. We found that, when sulfochlorides are added to berberrubine
2, 9-O-sulfonates of berberrubine are predominantly formed; when berberrubine 2 is added
to pre-generated sulfenes, sultones are the only isolated products.
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Scheme 8. Design of the experiment leading to selective formation of sultone 10a–d from berberrubine 2 and alkyl-
sulphochlorides 9a–d.
2.1.3. Structure Elucidation
The molecular structures of the sultones 10a–d were determined using NMR and HR-
MS. In the 1H NMR spectrum of compound 10a, the characteristic signals of the sultone
cycle are observed (Figure 3). The protons H-8, H-1′ and H-2′ represent the AB2 system.
The signals of H-1′ and H-2′ protons have the same multiplet (doublet of doublets). The
signal of the H-8 proton has the form of a triplet.
Figure 3. Fragment of 1H NMR spectrum of compound 10a.
In the 1H NMR spectra of the cyclic sulfonates 10a–d, one set of signals is present.
The H-8 proton signal in the spectra of compounds 10b–d is in the form of a doublet.
The spin–spin interaction constants of H-8 and H-1′ protons vary from 4.81 to 5.07 Hz,
suggesting the formation of isomers with cis-location of these protons (Figure 4). The
molecular weights of the sultons 10a–d correspond to the calculated values.
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Figure 4. Structures of sultones 10b–d and dehidrosultone 16a.
The formation of a new C-C bond was also confirmed by 2D NMR. In the COSY
spectrum of compound 10b, the characteristic cross peak of H-8 and H-1′ protons is present.
We have shown that, upon incubation in the NMR tube in DMSO-d6, the cyclic
sulfonate 10a partially transforms into compound 16a (Figure 4). Dehydrosulphonate 16a
was isolated in small amounts by column chromatography and its structure was suggested
based on 1H NMR and HR-MS spectra. In the 1H NMR spectrum of compound 16a, the
disappearance of H-1′, H-2′ and H-8 protons signals was observed (Figure 5), but a new
signal in the near-aromatic region (δ = 6.07 m.p.) relating to the H-1′ proton appeared. This
strong shift into the weak field is due to the formed double bond, which is conjugated to
the aromatic system of the berberine scaffold. In the mass spectrum of compound 16a, a
peak of 397.0618 is observed, which corresponds to the product of dehydrogenation of
compound 10a.
Figure 5. 1H NMR spectrum of compound 16a.
Compound 16a appears to be an oxidation product of sultone 10a upon DMSO addtion.
We carried out a directed oxidation of compound 10a with chloranil as an oxidizing agent.
It was shown that the use of the oxidizer allowed the same reaction to be carried out within
1 h at room temperature (Scheme 9), compound 16a was isolated from the reaction mixture
by precipitation with the addition of water with a yield of 80%.
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Scheme 9. Sultone cycle oxidation with chloranil in DMSO.
2.1.4. Synthesis of 12-Bromineberberrubine Derivatives
It is known that the introduction of substituents into the berberine backbone often
results in the enhancement of certain biological activities. In particular, it is known that
the introduction of bromine at the 12th position of the backbone increased the inhibitory
activity of berberine sulfonates against Tdp1 [38]. In order to establish a structure-activity
relationship, we synthesized cyclic sultone derivatives from 12-bromberrubine.
We have shown that the reaction of sultones formation from 12-bromoberrubine
proceeds similarly to that of berberrubine. 12-Bromoberrubine 17 was obtained from
berberrubine 2 by the action of bromine in the presence of alkali in a mixture of dioxane
with water according to the procedure described by Nechepurenko et al. [44]. Then, it
reacted with sulfochlorides 9a–d by the method we developed for the synthesis of sultones
10a–d, namely, a suspension containing 12-Br-bererrubine 17 with triethylamine was added
dropwise to sulfene solutions 15a–d, which led to the formation of sultones 18a–d in yields
from 40% to 70% (Scheme 10). The reaction proceeds at room temperature (22 ◦C).
Scheme 10. Synthesis of 12-Br-substituted sultones.
In contrast to compounds 10a–d, their brominated analogues 18a–d precipitated
during the reaction and were separated from the reaction mixture by filtration in pure
form without chromatography. The structure of sultones 18a–d was confirmed by NMR
and HR-MS spectroscopies. The dehydrogenation of these compounds occurred under
MS conditions, and therefore, [M-2H]+ signals were observed in their spectra. In the 1H
NMR spectra of compounds 18b–d, the proton signal H-8 has a doublet form, the spin–
spin interaction constants of protons H-8 and H-1′ vary from 4.60 to 4.79 Hz, indicating a
cis-location of protons (Figure 6), as in the case of unbrominated analogues 3b–d.
Thus, we have studied the demethylated reaction at 9-O-position berberine and 12-
bromberberine derivatives with sulphochlorides and is shown that, in addition to the
previously described sulphonates, cyclic sulphonates (sultones) are also formed in the
reaction. The study of possible reaction pathways allowed for the selection of reaction
conditions that selectively led to sultones in high yields.
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Figure 6. Structure of compounds 18a–d.
2.2. Biological Assays
Previously, our group established the inhibitory activity of Tdp1, for 9-O-arylsulfonates
of berberine (compounds 19) and enhancement of inhibitory activity after the introduction
of bromine at position 12 of the skeleton (compounds 20). 9-O-Alkylsulphonates, both in
charged (compounds 3a–d) and reduced form (compounds 21a–d, Figure 7), are not active,
with IC50 values >15 µM.
Figure 7. Previously synthesized berberine derivatives tested against Tdp1.
In this work, newly synthesized sultones were tested for their inhibition of Tdp1.
Tdp1 activity was measured using a fluorescent biosensor as previously described [39]. The
biosensor is an oligonucleotide with a fluorophore (FAM) at the 5′-end and a fluorescence
quencher (BHQ1) at the 3′-end. Due to the activity of the enzyme, the quencher is removed,
which leads to an increase in the fluorescence intensity. Inhibitors prevent the removal of
the quencher, thus reducing the fluorescence intensity. The results are shown in Table 1.
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Table 1. Tdp1 inhibiting activity (IC50) of berberrubine sultones and their 12-brominated analogs.
Code IC50, µM
CC50, µM
HeLa Code IC50, µM
CC50, µM
HeLa
R = H 10a 1.53 ± 0.18 >100 18a 0.92 ± 0.05 >100
R = Me 10b 2.13 ± 0.16 >100 18b 1.13 ± 0.20 >100
R = Et 10c 5.50 ± 0.10 >100 18c 0.56 ± 0.02 >100
R = Pr 10d 1.12 ± 0.18 >100 18d 0.78 ± 0.03 >100
All new compounds with the cyclic sulfone fragment show inhibitory activity in
the micromole or submicromolar range. Introduction of bromine atom in a molecule
led to an increase in activity. As for the substituent in the sultone ring, there is no strict
correlation between the carbon chain length and inhibitory activity. Inhibitory activity,
comparable to that of sultone 10a, was found for its dehydrogenated analog compound
16a (IC50 2.50 ± 0.40 µM).
All compounds have no intrinsic toxicity in the concentration range up to 100 µM
(Figure 8) in HeLa cells, with the exception of 16a and berberine, which are toxic at
concentrations above 20 µM. 16a is slightly toxic (CC50 ~ 100 µM) and differs from non-
toxic 10a in the presence of a double bond in the sultone cycle. The original berberine 1 is
toxic to HeLa cells with a cytotoxic concentration (CC50) of 20 µM, which is consistent with
the literature data [45].
Figure 8. The cytotoxicity of the sultones against HeLa cells, as measured by theEZ4U test.
As already mentioned, we have previously shown that various Tdp1 inhibitors en-
hanced the cytotoxic and antitumor effects of topotecan [21–30]. In this work, we also
tested the ability of the berberrubine sultones to sensitize cells to the action of topotecan.
For this, we chose a non-toxic concentration of Tdp1 inhibitors at 20 µM and varied the
concentrations of topotecan. As shown in Figure 9, only compound 18c exhibited the most
pronounced and statistically significant (Mann—Whitney U-test, p = 0.05) sensitizing effect.
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Figure 9. The influence of the berberrubine sultones at 20 µM on topotecan cytotoxicity. Error bars
show standard deviations.
Effective inhibition of Tdp1 and low toxicity make the berberrubine sultones promising
candidates for the further development of tumor cell sensitizers to anticancer drugs.
2.3. Molecular Modelling
Berberine derivatives were docked into the binding site of the Tdp1 structure (PDB ID:
6DIE, resolution 1.78 Å) [41], with three water molecules retained (HOH 814, 821 and 1078).
It has been shown that keeping these crystalline water molecules improves the prediction
quality of the docking scaffold (see the Methodology section for further information) [25].
The binding predictions of the four scoring functions used are given in Table S1; all the
ligands show reasonable scores. When the predicted configurations were analyzed, two
main binding modes emerged, depending on the scoring function used and the type of
derivative. Both configurations involve hydrogen bonding via the 1,4-butanesultone ring.
In order to check which conformation is more stable, 10 ps molecular dynamics (MD) runs
at 1000 K were conducted with derivative 18a. It is predicted to be bound to the protein
in both conformations depending on the scoring function. The results indicate that both
conformations are stable for the 10 ps run, e.g., the hydrogen bonding networks between
the ligand and Tdp1 were not broken. Thus, it can be concluded that both conformations
are viable, and they are shown in Figure 10.
In both predicted poses for 18a, the sulfonate ring moiety plays a major role in
the hydrogen bonding to the Tdp1 enzyme. Both form hydrogen bonds to Ser399 and
Lys495 via the sulfonyl moiety. His493 is predicted to bind to the ring forming oxygen for
GoldScore, but to Asn516 for ChemPLP. In both scenarios, the methoxy group is involved
in hydrogen bonding to the enzyme, but according to the MD runs, it is not very stable
and often breaks. In general, both predicted conformations are plausible, with a good fit
into the binding site, blocking access to His493, one of the crucial amino acid residues for
catalytic activity. Interestingly, the binding mode of the berberine derivatives presented in
this study differs from previously reported berberine derivatives for Tdp1 inhibition [38].
This can be explained by the lack of the 1,4-butanesultone ring in these berberine ligands,
which is clearly the main hydrogen bonding motive in the derivatives presented here. The
driving force of the previously reported ligands is most likely a lone pair—π stacking with
a fluorinated phenyl moiety absent in the ligands in this study. Additionally, derivatives
21a and 21b, which do not have the 1,4-butanesultone ring scaffold and are inactive at
>15 µM, are not predicted to have a specific binding mode, each scoring function offers a
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different solution, further strengthening the argument for the importance of this ring motif
(see Figure 7). Finally, the bromine moiety in the previously reported ligands is predicted
to form weak hydrogen bonds with His493 [38]; this is not seen for the berberine series
presented here, where the bromine is pointing towards the aqueous phase and its effect on
increased binding can be explained in terms of solvent entropic effects (see the Chemical
Space Section).
Figure 10. The docked configuration of 18a in the binding site of Tdp1 as predicted by the GoldScore (ball and stick) and
ChemPLP (stick) scoring functions. (A) The docked overlaid conformations for the GoldScore and ChemPLP predictions.
The hydrogen bonding sulfonate moiety is circled in green. (B) The protein surface is rendered; blue depicts regions with
a partial positive charge on the surface; red depicts regions with a partial negative charge and grey shows neutral areas.
The ligand occupies the binding pocket, blocking access to it in both predicted configurations. (C,D) Hydrogen bonds are
shown as green lines between the ligand (C), as predicted by GoldScore with amino acids Asn283, Ser399, His493 and
Lys495; (D) was predicted by ChemPLP with amino acids Ser399, Lys495 and Asn516.
The co-crystalized ligand benzene-1,2,4-tricarboxylic acid forms hydrogen bonds with
the side chains of Ser399, His493 and Lys495 [41], i.e., the same amino acid residues as
18a. In general, His263 [35,46], His493 [38,47] or both [33,48] are usually predicted to have
direct hydrogen bonding to the active ligands, as well as Lys495 [25,30], irrespective of the
ligand molecular type used. This is easily understood since these three amino acid residues
act as the catalytic scaffold for disengaging DNA from Top1.
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2.4. Chemical Space
The calculated molecular descriptors MW (molecular weight), log P (water-octanol
partition coefficient), HD (hydrogen bond donors), HA (hydrogen bond acceptors), PSA
(polar surface area) and RB (rotatable bonds)) are given in Table S2. The MW of the ligands
lie in the range of 399.4 and 520.4 g mol−1, falling into drug-like chemical space and for
two derivatives in Known Drug Space (KDS). Obviously, the brominated derivatives have
higher MW. The Log P values are very modest, lying between 2.0 and 3.6; in the lead-like
and drug-like chemical spaces like the other four descriptors (for the definition of lead-like,
drug-like and Known Drug Space regions see Reference [49] and Table S3). When the
activity of the ligands is plotted against the molecular descriptors strong correlation is seen
with both MW and log P, as shown in Figure 11. Derivative 10c is an outlier and is omitted,
as well as derivatives 21a and 21b, which are practically inactive.
Figure 11. The correlation of the IC50 values of the ligands with MW (A) and log P (B). A very good correlation is seen for
both molecular descriptors. Derivative 10c is an outlier and not included. Additionally, derivatives 21a and 21b are omitted
since they are inactive.
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As can be seen in Figure 11, a strong correlation is seen with both MW and log P with
higher numbers favoring better IC50 values. The HD and HA do not correlate with the
activity, but PSA (R2—0.257) and RB (R2—0.324) do to some extent. It is therefore clear
from these results that increased MW and log P favor improved binding to Tdp1. The
same trend is seen for deoxycholic acid steroid derivatives, which are also excellent Tdp1
inhibitors [48].
The Known Drug Indexes (KDIs) for the ligands were calculated to gauge the balance
of the molecular descriptors (MW, log P, HD, HA, PSA and RB). This method is based on
the analysis of drugs in clinical use, i.e., the statistical distribution of each descriptor is
fitted to a Gaussian function and normalized to 1, resulting in a weighted index. Both the
summation of the indexes (KDI2a) and multiplication (KDI2b) methods were used [50], as
shown for KDI2a in Equation (1) and for KDI2b in Equation (2); the numerical results are
given in Table S2 in the Supplementary Materials.
KDI2a = IMW + Ilog P + IHD + IHA + IRB + IPSA (1)
KDI2b = IMW × Ilog P × IHD × IHA × IRB × IPSA (2)
The KDI2a values for the ligands range from 5.16 to 5.57 with a theoretical maximum
of 6 and the average of 4.08 (±1.27) for known drugs. These values are very good, since
most of the descriptors lie within the lead and drug-like boundaries of chemical space.
KDI2b range from 0.39 to 0.62, with a theoretical maximum of 1 and with a KDS average
of 0.18 (±0.20). Again, very good values are obtained for the ligands even though the
KDI2b index is more sensitive than KDI2a to outliers, since multiplication of small numbers
leads to smaller numbers. KDI indexes were plotted against the IC50 values with the same
ligands as for MW and log P and the results are shown in Figure 12.
For both KDI indexes, lower values result in better activity; more lipophilic and larger
compounds are pushed into the catalytic cite by solvent entropic effects. The same trend is
seen for deoxycholic acid steroid derivatives [48]. Therefore, the addition of bromine to the
ligands does not contribute to more bonding between the ligands and Tdp1 (see modelling
section), rather it increases the entropic push of the ligand into the binding pocket.
Figure 12. Cont.
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Figure 12. The correlations between KDI2a (A) and KDI2b (B) with their corresponding IC50 values. Smaller KDI values
favor increased activity.
3. Materials and Methods
3.1. Chemistry
General information. Reagents (berberine chloride, alkyl sulfochlorides, triethy-
lamine, sodium borohydride, chloranil) were purchased from commercial suppliers
(Sigma-Aldrich, Acros, TCI) and used as received. Berberrubine hydrobromide and 12-
bromoberberrubine were synthesized according to previously reported methods [44,51].
Solvents (dichloromethane, DMSO) were used after distillation. 1H and 13C NMR were
recorded at Bruker DRX-500 apparatus at 125.76 MHz (13C), Bruker AV-300 apparatus
at 300.13 MHz (1H) and 75.47 MHz (13C), Bruker AV-400 apparatus at 400.13 MHz (1H)
and 100.61 (13C), Bruker Avance—III 600 apparatusat 600.30 MHz (1H) and 150.95 MHz
(13C), Jin Hz; structure determinations by analyzing the 1H NMR spectra, including 1H-
1H double resonance spectra and 1H-1H 2D homonuclear correlation, J-modulated 13C
NMR spectra (JMOD), and 13C-1H 2D heteronuclear correlation with one-bond (C-H COSY,
1J(C,H) = 160 Hz, HSQC, 1J(C,H) = 145 Hz) and long-range spin-spin coupling constants
(COLOC, 2,3J(C,H) = 10 Hz, HMBC, 2,3J(C,H) = 7 Hz). HR-MS: DFS Thermo Scientific
spectrometer in a full scan mode (15–500 m/z, 70 eV electron impact ionization, direct
sample administration).
Spectral and analytical investigations were carried out at the Multi-Access Chemical
Research Center of Siberian Branch of Russian Academy of Sciences. All product yields are
given for pure compounds.
3.1.1. General Procedure for the Synthesis of Sultones 10a–d
The stirred solution of sulfochloride (1.5 mmol) with triethylamine (1.5 mmol) in
25 mL of dichloromethane suspension of berberrubine hydrobromide (1 mmol) with tri-
ethylamine (2.5 mmol) in 3 mL of dichloromethane was added dropwise at room tempera-
ture (22–24 ◦C). After completion, the reaction (monitored by TLC) mixture was washed
with water, organic layer dried with MgSO4. After purification by column chromatography
(eluent—dichloromethane: methanol, sorbent-silica gel), the products 10a–d were obtained.
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19-Methoxy-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.020,24]tetracosa-
5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (10a). Yield: 70%. HR-MS, m/z: found
399.0768. Calculated for (C20H17O6N132S1)+: 399.0771. NMR 1H (400 MHz, DMSO-d6, δ,
ppm): 2.73 (3H, m, H-3, H-4), 3.28–3.32 (1H, m, H-3), 3.80 (3H, s, OCH3), 4.11 (1H, t H-1),
4.56 (1H, d.d, J1 = 5.64 Hz, J2 = 11.89 Hz, H-23), 4.69 (1H, d.d, J1 = 5.64 Hz, J2 = 13.03 Hz,
H-23), 6.01 (2H, d.d, J1 = 9.60 Hz, J2 = 0.88 Hz, H-9), 6.37 (1H, s, H-6), 6.78 (1H, s, H-12),
6.90 (1H, d, J = 8.40 Hz, H-17), 7.07 (1H, d, J = 8.40 Hz, H-18), 7.35 (1H, s, H-15). NMR 13C
(100 MHz, CDCl3, δ, ppm): 29.37 (C-4), 44.47 (C-3), 48.46 (C-23), 55.78, 56.29 (C-1), (OCH3),
98.32 (C-15), 101.00 (C-9), 103.67 (C-12), 107.36 (C-16), 113.08 (C-18), 113.38 (C-24), 119.91
(C-17), 123.66 (C-13), 126.86 (C-16), 128.27 (C-5), 137.67 (C-14), 141.72 (C-20), 146.10 (C-7),
146.80 (C-11), 147.62 (C-19).
19-Methoxy-23-methyl-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.020,24]
tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (10b). Yield: 65%. HR-MS, m/z:
found 413.0924. Calculated for (C21H19O6N132S1)+: 413.0928. NMR 1H (600 MHz, DMSO-
d6, δ, ppm, J/Hz): 1.37 (3H, d, J = 6.69 Hz, H-1′), 2.69–2.84 (3H, m, H-3, H-4), 3.23–3.29 (1H,
m, H-3), 3.80 (3H, s, OCH3), 4.71 (1H, m, H-23), 4.90 (1H, d, J = 4.56 Hz, H-1), 4.99 (1H, s,
J = 4.74, H-1′), 6.01 (2H, d.d, J1 = 9.12 Hz, J2 = 1.00 Hz, H-9), 6.29 (1H, s, H-12), 6.76 (1H,
s, H-6), 6.87 (1H, d, J = 8.44 Hz, H-17), 7.05 (1H, d, J = 8.40 Hz, H-18), 7.37 (1H, s, H-15).
NMR 13C (100 MHz, DMSO-d6, δ, ppm): 9.73 (C-1′), 28.84 (C-4), 43.93 (C-3), 50.93, 56.03,
59.24 (OCH3, C-1, C-23), 96.88 (C-15), 101.13 (C-9), 103.83 (C-12), 107.69 (C-6), 110.92 (C-24),
113.37 (C-18), 119.96 (C-17), 123.52 (C-13), 127.48 (C-16), 129.02 (C-5), 136.67 (C-14), 141.19
(C-20), 145.39 (C-7), 146.60 (C-11), 147.34 (C-19).
23-Ethyl-19-methoxy-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.020,24]
tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (10c). Yield: 68%. HR-MS, m/z:
found 427.1068. Calculated for (C22H21O6N132S1)+: 427.1084. NMR 1H (400 MHz, DMSO-
d6, δ, ppm): 1.17 (3H, t, J = 7.58 Hz, H-2′), 1.57–1.66 (1H, m, H-1′), 2.02–2.09 (1H, m, H-1′),
2.76–2.83 (3H, m, H-3, H-4), 3.16–3.20 (1H, m, H-3), 3.79 (3H, s, OCH3), 4.48–4.53 (1H, m,
H-23), 4.97 (1H, d, J = 4.69 Hz, H-1), 6.02 (2H, d, J = 6.09 Hz, H-9), 6.23 (1H, s, H-6), 6.77 (1H,
s, H-12), 6.86 (1H, d, J = 8.57 Hz, H-17), 7.04 (1H, d, J = 8.57 Hz, H-18), 7.36 (1H, s, H-15).
NMR 13C (100 MHz, DMSO-d6, δ, ppm): 12.04 (C-2′), 18.15 (C-1′), 28.72 (C-4), 44.19 (C-3),
56.04 (OCH3), 57.72, 59.70 (C-1), (C-23), 96.04 (C-15), 101.11 (C-9), 103.86 (C-12), 107.69
(C-6), 112.00, 123.55, 127.17, 128,90 (C-5, C-24, C-16, C-13), 113.43 (C-18), 119.98 (C-17),
136.58 (C-14), 140.77 (C-20), 145.42 (C-7), 146.58 (C-11), 147.34 (C-19).
19-Methoxy-23-propyl-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.020,24]
tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (10d). Yield: 64%. HR-MS, m/z:
found 441.1220. Calculated for (C23H23O6N132S1)+: 441.1241. NMR 1H (400 MHz, DMSO-
d6, δ, ppm): 0.90 (3H, t, J = 6.89 Hz, H-3′), 1.55–1.74 (3H, m, H-2′, H-1′), 1.91–1.99 (1H, m,
H-1′), 2.76–2.83 (3H, m, H-3, H-4), 3.17–3.22 (1H, m, H-3), 3.79 (3H, s, OCH3), 4.57 (1H, m,
H-23), 5.01 (1H, d, J = 4.75 Hz, H-1), 6.01 (2H, d.d, J1 = 4.67 Hz, J2 = 0.77 Hz, C-9), 6.22 (1H,
s, H-6), 6.77 (1H, s, H-12), 6.86 (1H, d, J = 8.42 Hz, H-17), 7.04 (1H, d, J = 8.42 Hz, H-18),
7.36 (1H, s, H-15). NMR 13C (100 MHz, DMSO-d6, δ, ppm): 13.89 (C-3′), 20.24 (C-2′), 26.76
(C-1′), 28.70 (C-4), 44.19 (C-3), 56.00, 56.04, 59.70 (OCH3, C-1, C-23), 95.93 (C-15), 101.11
(C-9), 103.83 (C-12), 107.69 (C-6), 111.84, 123.52, 127.09, 128.87 (C-5, C-24, C-16, C-13), 113.37
(C-18), 119.97 (C-17), 136.57 (C-14), 140.68 (C-20), 145.39 (C-7), 146.57 (C-11), 147.33 (C-19).
19-Methoxy-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.020,24]tetracosa-
1(23),5,7(11),12,14,16,18,20(24)-octaene-22,22-dione (16a). The suspension of compound 10a
(399 mg, 1 mmol) in dimethyl sulfoxide (10 mL) and 246 mg (1 mmol) of chloranil was
added in one portion. The reaction mixture was stirred at room temperature for 1 h. After
that cold water was added and we observed the greenish-yellow precipitate formation.
The precipitate was filtered, washed with cold water and air-dried. 316 mg of product 16a
was obtained. Yield: 80%. HRMS, m/z: found 397.0618. Calculated for (C20H15O6N132S1)+:
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397.0615. NMR 1H (400 MHz, DMSO-d6, δ, ppm): 2.94 (2H, t, J = 6.23 Hz, H-4), 3.68 (2H,
t, J = 6.23 Hz, H-3), 3.91 (3H, s, OCH3), 6.07 (1H, s, H-23), 6.08 (2H, s, H-9), 6.95 (1H, s,
H-15 *), 7.03 (1H, s, H-12 *), 7.36 (1H, d, J = 8.70 Hz, H-18), 7.42 (1H, s, H-6 *), 7.52 (1H,
d, J = 8.70 Hz, H-17). NMR 13C (100 MHz, DMSO-d6, δ, ppm): 26.96 (C-4), 43.23 (C-3),
56.58 (OCH3), 83.79 (C-23), 101.40 (C-9), 101.45 (C-15), 104.89 (C-12), 107.60 (C-6), 111.88
(C-24), 118.26 (C-18), 121.76 (C-17), 122.48, 126.14, 128.98, 135.25 (C-5, C-16, C-14, C-13),
144.00 (C-1), 145.66, 145.83, 146.96 (C-7, C-11, C-20), 148.29 (C-19). Signals marked with *
can be swapped.
3.1.2. General Procedure for the Synthesis of Sultones 18a–d
The suspension of 0.22 mmol 12-bromoberberrubine in 3 mL of dichloromethane 0.091
mmol trimethylamine was added dropwise under stirring at room temperature (24 ◦C).
The resulting solution (solution 1) was left to stir for 5 min. The solution of 0.34 mmol
of sulfochloride in 25 mL of methylene chloride was added 0.34 mmol of triethylamine
(solution 2). Solution 1 was added to solution 2 dropwise. After 3 h, the resulting yellow
precipitate was filtered off, washed with 10 mL cold methylene chloride and the pure
product 18a–d was isolated.
17-Bromo-19-methoxy-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.020,24]
tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (18a). Yield: 40%. HR-MS, m/z:
found for (C20H16O6N179Br132S1-2H)+: 474.9723. Calculated for (C20H16O6N179Br132S1)+:
476.9876. NMR 1H (400 MHz, DMSO-d6, δ, ppm): 2.64–2.73 (1H, m, H-4), 2.78–2.86 (2H, m,
H-3, H-4), 3.28 (1H, m, H-3), 3.84 (3H, s, OCH3), 4.24 (1H, t, J = 12.37 Hz, H-1), 4.56 (1H,
d.d, J1 = 5.50 Hz, J2 = 11.50 Hz, H-23), 4.69 (1H, d.d, J1 = 5.50 Hz, J2 = 12.69 Hz, H-23), 6.02
(1H, s, H-9), 6.06 (1H, s, H-9), 6.25 (1H, s, H-6), 6.82 (1H, s, H-12), 7.32 (1H, s, J = 8.40 Hz,
H-18), 7.36 (1H, s, H-15). NMR 13C (100 MHz, DMSO-d6, δ, d.d.): 29.24 (C-4), 44.13 (C-3),
47.44 (C-23), 56.19, 57.23 (C-1), (OCH3), 96.42 (C-15), 101.85 (C-9), 104.44 (C-12), 108.29
(C-6), 113.59 (C-17), 115.03 (C-18), 117.53 (C-24), 123.83 (C-13), 126.59 (C-5), 130.05 (C-16),
137.37 (C-14), 144.88 (C-20), 146.30 (C-7), 147.34 (C-11), 148.45 (C-19).
17-Bromo-19-methoxy-23-methyl-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.
020,24]tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (18b). Yield: 45%. HR-MS,
m/z: found for (C21H18O6N179Br132S1-2H)+:·488.9878. Calculated for (C20H18O6N179Br132S1)+:
491.0033. NMR 1H (400 MHz, DMSO-d6, δ, ppm): 1.38 (3H, d, J = 6.75 Hz, H-1′), 2.77–2.84
(3H, m, H-4, H-3), 3.22–3.27 (1H, m, H-3), 3.83 (3H, s, OCH3), 4.73–4.80 (1H, m, H-23), 5.06
(1H, d, J = 4.71 Hz, H-1), 6.03 (1H, s, H-9), 6.06 (1H, s, H-9), 6.13 (1H, s, H-6), 6.82 (1H,
s, H-12), 7.29 (1H, s, H-18), 7.34 (1H, s, H-15). NMR 13C (100 MHz, DMSO-d6, δ, ppm):
9.65 (C-1′), 29.13 (C-4), 43.86 (C-3), 52.56 (C-23), 56.14, 59.71 (C-1), (OCH3), 95.09 (C-15),
100.91 (C-9), 103.98 (C-12), 107.19 (C-6), 113.05, 114.17 (C-17), (C-24), 116.68 (C-18), 123.34
(C-13), 126.14 (C-5), 128.42 (C-16), 136.29 (C-14), 142.34 (C-20), 145.85 (C-7), 146.70 (C-11),
147.80 (C-19).
17-Bromo-23-ethyl-19-methoxy-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.
020,24]tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (18c). Yield: 70%. HR-MS, m/z:
found for (C22H20O6N179Br132S1-2H)+:·503.0033. Calculated for (C22H20O6N179Br132S1)+:
505.0189. NMR 1H (400 MHz, DMSO-d6, δ, ppm): 1.15 (3H, t, J = 7.39 Hz, H-2′), 1.54–1.66
(1H, m, H-1′), 1.96–2.06 (1H, m, H-1′), 2.78–2.93 (3H, m, H-4, H-3), 3.14–3.20 (1H, m, H-3),
3.82 (3H, s, OCH3), 4.50–4.56 (1H, m, H-23), 5.17 (1H, d, J = 4.60 Hz, H-1), 6.02 (1H, s, H-9),
6.03 (1H, s, H-9), 6.05 (1H, s, H-6), 6.82 (1H, s, H-12), 7.30 (1H, s, H-18), 7.33 (1H, s, H-15).
NMR 13C (100 MHz, DMSO-d6, δ, ppm): 12.33 (C-2′), 18.69 (C-1′), 28.89 (C-4), 44.16 (C-3),
56.80, 59.02, 59.95 (C-1), (C-23), (OCH3), 93.23 (C-15), 101.62 (C-9), 104.15 (C-12), 108.13
(C-6), 113.82, 114.47 (C-17), (C-24), 117.35 (C-18), 123.39 (C-13), 126.11 (C-5), 129.98 (C-16),
136.19 (C-14), 143.19 (C-20), 145.98 (C-7), 146.99 (C-11), 148.22 (C-19).
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17-Bromo-19-methoxy-23-propyl-8,10,21-trioxa-22λ6-thia-2-azahexacyclo[14.7.1.02,14.05,13.07,11.
020,24]tetracosa-5,7(11),12,14,16,18,20(24)-heptaene-22,22-dione (18d). Yield: 55%. HR-MS,
m/z: found for (C23H22O6N179Br132S1-2H)+: 517.0189. Calculated for (C23H22O6N179Br132S1)+:
519.0346. NMR 1H (400 MHz, DMSO-d6, δ, ppm): 0.89 (3H, t, J = 7.12 Hz, H-3′), 1.51–1.69
(2H, m, H-2′), 1.64–1.73 (1H, m, H-1′), 1.87–1.95 (1H, m, H-1′), 2.78–2.92 (3H, m, H-4, H-3),
3.14–3.21 (1H, m, H-3), 3.82 (3H, s, OCH3), 4.57–4.62 (1H, m, H-23), 5.19 (1H, d, J = 4.69
Hz, H-1), 6.01 (1H, s, H-9), 6.03 (1H, s, H-9), 6.05 (1H, s, H-6), 6.82 (1H, s, H-12), 7.26 (1H, s,
H-18), 7.31 (1H, s, H-15). NMR 13C (100 MHz, DMSO-d6, δ, ppm): 13.87 (C-3′), 20.30 (C-2′),
26.99 (C-1′), 28.60 (C-4), 43.93 (C-3), 56.66, 57.08, 59.67 (C-1), (C-23), (OCH3), 92.97 (C-15),
101.40 (C-9), 103.86 (C-12), 107.87 (C-6), 113.68, 114.13 (C-17), (C-24), 117.18 (C-18), 123.19
(C-13), 125.87 (C-5), 129.70 (C-16), 136.01 (C-14), 142.86 (C-20), 145.78 (C-7), 146.72 (C-11),
147.95 (C-19).
3.2. Biology
3.2.1. Detection of Tdp1 Activity
Tdp1 activity was detected, as described in the work in Reference [39], and consists of
fluorescence intensity measurement in a reaction of quencher removal from a fluorophore
quencher–coupled DNA oligonucleotide catalyzed by Tdp1. The reaction was carried out
at different concentrations of inhibitors (the control samples contained 1% of DMSO). The
reaction mixtures contained Tdp1 buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, and 7 mM
β-mercaptoethanol), 50 nM biosensor, and an inhibitor being tested. Purified Tdp1 (1.5 nM)
triggered the reaction. The biosensor (5′-[FAM] AAC GTC AGGGTC TTC C [BHQ]-3′) was
synthesized in the Laboratory of Biomedical Chemistry at the Institute of Chemical Biology
and Fundamental Medicine (Novosibirsk, Russia).
The reactions were incubated on a POLARstar OPTIMA fluorimeter (BMG LABTECH,
GmbH, Ortenberg, Germany) to measure fluorescence every 55 s (ex. 485/em. 520 nm)
during the linear phase (here, data from minute 0 to minute 8). The values of IC50 were
determined using a six-point concentration response curve in a minimum of three indepen-
dent experiments and were calculated using MARS Data Analysis 2.0 (BMG LABTECH,
Ortenberg, Germany).
3.2.2. Cytotoxicity Assays
Cytotoxicity of the compounds to HeLa (human cervical cancer) cell line was examined
using the EZ4U Cell Proliferation and Cytotoxicity Assay (Biomedica, Vienna, Austria),
according to the manufacturer’s protocols. The cells were grown in Iscove’s modified
Dulbecco’s medium (IMDM) with 40 µg/mL gentamicin, 50 IU/mL penicillin, 50 µg/mL
streptomycin (MP Biomedicals, Waltham, MA, USA), and 10% of fetal bovine serum (Biolot,
Saint Petersburg, Russia) in a 5% CO2 atmosphere. After the formation of a 30–50%-
monolayer, the tested compounds were added to the medium. The volume of the added
reagents was 1/100 of the total volume of the culture medium, and the amount of DMSO
was 1% of the final volume. Control cells were grown in the presence of 1% DMSO. The
cell culture was monitored for 3 days.
3.3. Molecular Modeling and Screening
The compounds were docked against the crystal structure of Tdp1 (PDB ID: 6DIE,
resolution 1.78 Å) [41], which was obtained from the Protein Data Bank (PDB) [52,53]. The
Scigress version FJ 2.6 program [54] was used to prepare the crystal structure for docking,
i.e., the hydrogen atoms were added, the co-crystallized ligand benzene-1,2,4-tricarboxylic
acid was removed as well as crystallographic water molecules, except HOH 814, 821 and
1078. The waters were set on toggle-bound or displaced by the ligand during docking,
and spin-automatic optimization of the orientation of the hydrogen atoms. The Scigress
software suite was also used to build the inhibitors and the MM2 [55] force field was
applied to identify the global minimum using the CONFLEX method [56], followed by
structural optimization, as well as running the 10 ps molecular dynamics (MD) run at
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1000 K. The docking center was defined as the position of a carbon on the ring of the
co-crystallized benzene-1,2,4-tricarboxylic acid (x = −6.052, y = −14.428, z = 33.998) with
10 Å radius. Fifty docking runs were allowed for each ligand with default search efficiency
(100%). The basic amino acids lysine and arginine were defined as protonated. Furthermore,
aspartic and glutamic acids were assumed to be deprotonated. The GoldScore (GS) [57]
and ChemScore (CS) [58,59] ChemPLP (Piecewise Linear Potential) [60] and ASP (Astex
Statistical Potential) [61] scoring functions were implemented to predict the binding modes
and relative energies of the ligands using the GOLD v5.4.1 software suite.
The QikProp 6.2 [62] software package was used to calculate the molecular descriptors
of the molecules. The reliability of it is QikProp, which is established for the calculated
descriptors [63]. The Known Drug Indexes (KDI) were calculated from the molecular de-
scriptors as described by Eurtivong and Reynisson [50]. For application in Excel, columns
for each property were created and the following equations used to derive the KDI num-
bers for each descriptor: KDI MW: = EXP(−((MW − 371.76)2)/((2 × 112.76)2)), KDI Log
P: = EXP(−((LogP − 2.82)2)/((2 × 2.21)2)), KDI HD: = EXP(−((HD − 1.88)2)/((2 × 1.7)2)),
KDI HA: = EXP(−((HA − 5.72)2)/((2 × 2.86)2)), KDI RB = EXP(−((RB − 4.44)2)/((2 ×
3.55)2)), and KDI PSA: =EXP(−((PSA − 79.4)2)/((2 × 54.16)2)). These equations could
simply be copied into Excel and the descriptor name (e.g., MW) substituted with the value
in the relevant column. In order to derive KDI2A, this equation was used: = (KDI MW +
KDI LogP + KDI HD + KDI HA + KDI RB + KDI PSA) and for KDI2B = (KDI MW × KDI
LogP × KDI HD × KDI HA × KDI RB × KDI PSA).
4. Conclusions
A new type of berberine derivatives with a fused sultone ring has been discovered.
Compounds were obtained in the reaction of berberrubine with sulphochlorides, as well as
with classical sulphonates. Investigation of the reaction mechanisms suggests pathways
for the formation of sultones, including both a stepwise and synchronous addition of
sulphochloride with the latter in the main pathway. Based on this observation, conditions
for the selective formation of sultones in good yields were developed. We showed that
brominated analogues of berberrubine reacted with sulphochlorides similarly to berber-
rubine with the formation of 12-Br-sultones. All the synthesized compounds were tested
for their inhibitory activity against Tdp1, a promising target for antitumor therapie. It was
shown that these compounds, unlike their non-cyclic counterparts (not exhibiting activity
against Tdp1) are active against Tdp1 at micromolar and submicromolar concentrations,
and the introduction of Br to the 12 position contributes to an increase in the targeting
activity. Compound 18c can be considered to be the lead compound, since it most effec-
tively inhibits Tdp1, is non-toxic, and enhances the cytotoxic effect of topotecan on HeLa
cells. The modelling revealed two main binding modes of the ligands, both involving the
1,4-butanesultone ring system. The bromine substituent is not predicted to form direct
bonds with Tdp1, rather it is pointing into the water environment and contributes to the
binding by aiding the entropic push of the brominated ligands into the binding pocket.
Supplementary Materials: The following are available online, NMR 1H and 13C spectra of the
compounds 10a–10d, 16a, 18a–18d, 2D NMR (COSY and HSQC) spectra of the compound 10b,
Table S1: The binding affinities as predicted by the scoring functions used, Table S2: The molecular
descriptors and their corresponding Known Drug Indexes 2a and 2b (KDI2a/2b), Table S3: Definition
of lead-like, drug-like and Known Drug Space (KDS) in terms of molecular descriptors. The values
given are the maxima for each descriptor for the volumes of chemical space used.
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